ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RKT Reckitt Benckiser Group Plc

4,476.00
7.00 (0.16%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reckitt Benckiser Group Plc LSE:RKT London Ordinary Share GB00B24CGK77 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  7.00 0.16% 4,476.00 4,483.00 4,485.00 4,521.00 4,468.00 4,472.00 3,319,901 16:35:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Soap And Other Detergents 14.61B 1.64B 2.3088 19.42 31.91B

Reckitt Benckiser Ends Talks to Buy Pfizer's Consumer Health-Care Business

22/03/2018 7:52am

Dow Jones News


Reckitt Benckiser (LSE:RKT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Reckitt Benckiser Charts.
   By Carlo Martuscelli 
 

Reckitt Benckiser Group PLC (RB.LN) said Thursday that it has ended discussions about its potential acquisition of Pfizer Inc.'s (PFE) consumer health-care business.

The consumer-goods company said it had only been looking to buy part of the business because the whole unit did not meet its acquisition criteria, but this had turned out to be impossible.

"Our priority remains organic growth, including the completion of the integration of Mead Johnson Nutrition and creating further value from reorganizing into two new business units--Health and Hygiene Home," Reckitt Benckiser Chief Executive Rakesh Kapoor said.

Pfizer said last October that it was considering a sale or spinoff of its over-the-counter unit, which makes Advil ibuprofen and Centrum multivitamin pills. The unit is expected to fetch more than $10 billion, according to analysts.

This leaves GlaxoSmithKline PLC (GSK.LN) in the running to buy the unit. The pharmaceutical major said in October said it was considering a bid for the unit should the U.S. company put it up for sale.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

March 22, 2018 03:37 ET (07:37 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year Reckitt Benckiser Chart

1 Year Reckitt Benckiser Chart

1 Month Reckitt Benckiser Chart

1 Month Reckitt Benckiser Chart

Your Recent History

Delayed Upgrade Clock